Meeting
2017 ASCO Annual Meeting
Survival by HER2 receptor status in stage IV breast cancer: SEER 2010-2012.
Authors
Alexandra Thomas
Wake Forest Baptist School of Medicine, Winston-Salem, NC
Alexandra Thomas , Seema Ahsan Khan , Charles Lynch , Mary Chen Schroeder
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 35, 2017 (suppl; abstr 1032)
DOI
10.1200/JCO.2017.35.15_suppl.1032
Abstract #
1032
Poster Bd #
24
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score.
First Author: Seunghwan Shin
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).
First Author: Erica Michelle Stringer-Reasor
Poster
2014 ASCO Annual Meeting
Racial/ethnic (RE) differences in the occurrence of HER2 and hormone receptor (HR)-defined breast cancer (BC) in California (CA).
First Author: Scarlett Lin Gomez
Poster
2024 ASCO Annual Meeting
Multilevel factors associated with delays to neoadjuvant chemotherapy among young adults with operable breast cancer.
First Author: Melissa Beauchemin